Stockreport

Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

Climb Bio, Inc.  (CLYM) 
PDF First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026  Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and P [Read more]